98%
921
2 minutes
20
Since very few unusual BCR/ABL fusion transcripts in chronic myeloid leukemia have been reported, no clear evidence exists concerning their clinical and prognostic implications. We describe here a CML case with normal karyotype at standard cytogenetics and an atypical e6a2 BCR/ABL fusion transcript, presenting at diagnosis isolated thrombocytosis and mild leukopenia; the patient, who was tested negative for JAK2 mutation, obtained a complete response to imatinib. The few previous observations from literature are also reviewed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.leukres.2007.05.022 | DOI Listing |
Background: This study aims to gain further insights into the characteristics of the rare subtype of acute myeloid leukemia (AML) with BCR∷ABL by analyzing laboratory detection results of various gene mutations, such as NPM1.
Methods: Laboratory detection results of multiple gene missense mutations, including NPM1, were analyzed in a case of primary AML with BCR∷ABL.
Results: The patient exhibited morphological features of acute leukemia in the bone marrow.
Zhonghua Xue Ye Xue Za Zhi
July 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes o
The evolving stratified treatment approach based on molecular genetic alterations and minimal residual disease (MRD) monitoring has established a strong foundation for clinically managing Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL). However, with the growing use of immune-targeted therapies and the increased sensitivity of detection technologies, discrepancies in MRD assessment have emerged in some patients with Ph(+) ALL, particularly where BCR:: ABL1-based MRD levels remain consistently elevated compared to those detected by alternative methods. Research suggests that this persistent BCR:: ABL1 positivity may not solely reflect residual lymphoblasts but may also indicate the involvement of multilineage hematopoietic cells.
View Article and Find Full Text PDFPLoS One
August 2025
Faculty of Medical Technology, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Chronic myeloid leukemia (CML) is a hematologic malignancy originating from hematopoietic stem cells and driven by the BCR-ABL fusion oncogene. Imatinib (IM), a tyrosine kinase inhibitor, is commonly used as a frontline therapy for CML. However, some patients exhibit primary resistance or show persistent molecular evidence of disease despite treatment.
View Article and Find Full Text PDFBiomed Chromatogr
October 2025
Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India.
Vodobatinib is a third-generation Bcr-Abl 1 inhibitor, being used in chronic myeloid leukemia treatment. Herein, we report a validated LC-MS/MS method for quantifying vodobatinib from rat dried blood spot (DBS) as per FDA guidelines. Methanol was used as a solvent to extract vodobatinib from the DBS discs.
View Article and Find Full Text PDFAfr Health Sci
June 2025
Department of Hematology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China.
The Philadelphia chromosome is usually express on about 30% acute B lymphoblastic leukemia. Most of Ph-positive acute lymphoblastic leukemia patients have ela2 BCR-ABL transcripts, other atypical fusion genes such as ela3 have been rare reported. We reported a case of Ph-positive B-acute lymphoblastic leukemia with a scare ela3 fusion transcript.
View Article and Find Full Text PDF